High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome.
Nithya KrishnamurthyDaisuke NishizakiScott M LippmanHirotaka MiyashitaMary K NeslineSarabjot PablaJeffrey M ConroyPaul DePietroShumei KatoRazelle KurzrockPublished in: Therapeutic advances in medical oncology (2024)
High CTLA-4, especially when combined with high PD-L1 transcript expression, was a significant positive predictive biomarker for better outcomes (PFS and OS) in patients on immunotherapy.